Biogen

Biogen, founded in 1978, is a pioneering biotechnology company specializing in serious neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, Biogen leads in multiple sclerosis treatments and introduced the first approved therapy for spinal muscular atrophy.  
The company actively researches treatments for Alzheimer's, Parkinson's, and ALS, pushing the boundaries of neuroscience. With approximately 7,000 employees worldwide, Biogen maintains a global presence through direct affiliates in 30 countries and distribution partners in over 50 more.  
The company's commitment to cutting-edge science and medicine drives its mission to discover, develop, and deliver innovative therapies. Biogen also manufactures and commercializes biosimilars of advanced biologics, expanding access to essential treatments. The company's focus on neurology and rare diseases positions it at the forefront of addressing some of the most challenging health issues facing society today. Biogen's dedication to scientific excellence and patient care continues to shape its role as a leader in the biotechnology industry.